KEYNOTE-010: Pembrolizumab, anti-PD-1, for advanced NSCLC with PD-L1 expression - European Medical Journal

KEYNOTE-010: Pembrolizumab, anti-PD-1, for advanced NSCLC with PD-L1 expression

Oncology

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD, from Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, discusses data from KEYNOTE-010, a phase 2/3 study of pembrolizumab, anti-PD-1 antibody, versus docetaxel for patients with PD-L1-positive non-small cell lung cancer (NSCLC) who had disease progression after platinum-containing systemic therapy.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.